Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Design
  4. Volume 30, Issue 33
  5. Article
Volume 30, Issue 33
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Loop diuretics are the cornerstone of decongestive therapy in patients presenting with acute heart failure and have been extensively studied in randomized clinical trials. Therefore, in current guidelines, they are the only drug with a class I recommendation to treat signs and symptoms of congestion when present. However, the percentage of patients achieving successful decongestion is suboptimal, and diuretic resistance frequently develops. Patients with a poor response to loop diuretics and those discharged with residual signs of congestion are characterized by a worse prognosis over time. Recently, a renovated interest in different diuretic classes sprouted among heart failure researchers in order to improve decongestion strategies and ameliorate short- and long-term clinical outcomes. Randomized clinical trials investigating associations among diuretic classes and loop diuretics have been performed but yielded variable results. Therefore, despite initial evidence of a possible benefit from some of these compounds, a definite way to approach diuretic resistance diuretic combination therapy is still missing. The aim of this review is to summarize current clinical evidence on the use of diuretic combination therapy in patients with acute heart failure and to suggest a possible approach to avoid or counteract diuretic resistance.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128316596240625110337
2024-07-12
2024-12-26

  • From This Site

    /content/journals/cpd/10.2174/0113816128316596240625110337
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ArrigoM JessupM MullensW Acute heart failure.Nat Rev Dis Primers2020611610.1038/s41572‑020‑0151‑7
     [Google Scholar]
  2. McDonaghT.A. MetraM. AdamoM. GardnerR.S. BaumbachA. BöhmM. BurriH. ButlerJ. ČelutkienėJ. ChioncelO. ClelandJ.G.F. CoatsA.J.S. Crespo-LeiroM.G. FarmakisD. GilardM. HeymansS. HoesA.W. JaarsmaT. JankowskaE.A. LainscakM. LamC.S.P. LyonA.R. McMurrayJ.J.V. MebazaaA. MindhamR. MunerettoC. Francesco PiepoliM. PriceS. RosanoG.M.C. RuschitzkaF. Kathrine SkibelundA. de BoerR.A. Christian SchulzeP. AbdelhamidM. AboyansV. AdamopoulosS. AnkerS.D. ArbeloE. AsteggianoR. BauersachsJ. Bayes-GenisA. BorgerM.A. BudtsW. CikesM. DammanK. DelgadoV. DendaleP. DilaverisP. DrexelH. EzekowitzJ. FalkV. FauchierL. FilippatosG. FraserA. FreyN. GaleC.P. GustafssonF. HarrisJ. IungB. JanssensS. JessupM. KonradiA. KotechaD. LambrinouE. LancellottiP. LandmesserU. LeclercqC. LewisB.S. LeyvaF. LinhartA. LøchenM-L. LundL.H. ManciniD. MasipJ. MilicicD. MuellerC. NefH. NielsenJ-C. NeubeckL. NoutsiasM. PetersenS.E. Sonia PetronioA. PonikowskiP. PrescottE. RakishevaA. RichterD.J. SchlyakhtoE. SeferovicP. SenniM. SitgesM. Sousa-UvaM. TocchettiC.G. TouyzR.M. TschoepeC. WaltenbergerJ. AdamoM. BaumbachA. BöhmM. BurriH. ČelutkienėJ. ChioncelO. ClelandJ.G.F. CoatsA.J.S. Crespo-LeiroM.G. FarmakisD. GardnerR.S. GilardM. HeymansS. HoesA.W. JaarsmaT. JankowskaE.A. LainscakM. LamC.S.P. LyonA.R. McMurrayJ.J.V. MebazaaA. MindhamR. MunerettoC. PiepoliM.F. PriceS. RosanoG.M.C. RuschitzkaF. SkibelundA.K. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur. Heart J.202142363599372610.1093/eurheartj/ehab36834447992
     [Google Scholar]
  3. MullensW. DammanK. HarjolaV.P. MebazaaA. Brunner-La RoccaH.P. MartensP. TestaniJ.M. TangW.H.W. OrsoF. RossignolP. MetraM. FilippatosG. SeferovicP.M. RuschitzkaF. CoatsA.J. The use of diuretics in heart failure with congestion a position statement from the Heart Failure Association of the European Society of Cardiology.Eur. J. Heart Fail.201921213715510.1002/ejhf.136930600580
     [Google Scholar]
  4. MoonK.T. Diuretic strategies in persons with acute decompensated heart failure.Am. Fam. Physician2012859E110.1056/NEJMOA1005419/SUPPL_FILE/NEJMOA1005419_DISCLOSURES.PDF
     [Google Scholar]
  5. BartB.A. GoldsmithS.R. LeeK.L. GivertzM.M. O’ConnorC.M. BullD.A. RedfieldM.M. DeswalA. RouleauJ.L. LeWinterM.M. OfiliE.O. StevensonL.W. SemigranM.J. FelkerG.M. ChenH.H. HernandezA.F. AnstromK.J. McNultyS.E. VelazquezE.J. IbarraJ.C. MascetteA.M. BraunwaldE. Ultrafiltration in decompensated heart failure with cardiorenal syndrome.N. Engl. J. Med.2012367242296230410.1056/NEJMoa121035723131078
     [Google Scholar]
  6. WilcoxC.S. TestaniJ.M. PittB. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure.Hypertension20207641045105410.1161/HYPERTENSIONAHA.120.1520532829662
     [Google Scholar]
  7. Rubio-GraciaJ. DemisseiB.G. ter MaatenJ.M. ClelandJ.G. O’ConnorC.M. MetraM. PonikowskiP. TeerlinkJ.R. CotterG. DavisonB.A. GivertzM.M. BloomfieldD.M. DittrichH. DammanK. Pérez-CalvoJ.I. VoorsA.A. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure.Int. J. Cardiol.201825818519110.1016/j.ijcard.2018.01.06729544928
     [Google Scholar]
  8. CoiroS. RossignolP. AmbrosioG. CarluccioE. AlunniG. MurroneA. TrittoI. ZannadF. GirerdN. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure.Eur. J. Heart Fail.201517111172118110.1002/ejhf.34426417699
     [Google Scholar]
  9. PagnesiM. GhiraldinD. VizzardiE. ChiaritoM. StolfoD. BaldettiL. AdamoM. LombardiC.M. InciardiR.M. TomasoniD. LoiaconoF. MaccalliniM. VillaschiA. GaspariniG. MontellaM. ContessiS. CocianniD. PerottoM. BaroneG. SartoriS. DavisonB.A. MerloM. CappellettiA.M. SinagraG. PiniD. MetraM. Detailed assessment of the “i need help” criteria in patients with heart failure: Insights from the HELP-HF registry.Circ. Heart Fail.20231612e01100310.1161/CIRCHEARTFAILURE.123.01100337909222
     [Google Scholar]
  10. RaoV.S. Ivey-MirandaJ.B. CoxZ.L. RielloR. GriffinM. FlemingJ. SoucierR. SangkachandP. O’BrienM. LoRussoF. D’AmbrosiJ. ChurchwellK. MahoneyD. BellumkondaL. AsherJ.L. MaulionC. TurnerJ.M. WilsonF.P. CollinsS.P. TestaniJ.M. Natriuretic equation to predict loop diuretic response in patients with heart failure.J. Am. Coll. Cardiol.202177669570810.1016/j.jacc.2020.12.02233573739
     [Google Scholar]
  11. PellegrinoM. VillaschiA. GhiandaD. LoiaconoF. PagliaroB.R. FerraroF. LorenziG.M. PiniD. Urinary sodium-guided intravenous diuretic therapy in acute heart failure: Transitioning from art to science?J. Card. Fail.202329121678168210.1016/j.cardfail.2023.07.01237582420
     [Google Scholar]
  12. ter MaatenJ.M. BeldhuisI.E. van der MeerP. KrikkenJ.A. PostmusD. CosterJ.E. NieuwlandW. van VeldhuisenD.J. VoorsA.A. DammanK. Natriuresis-guided diuretic therapy in acute heart failure: A pragmatic randomized trial.Nat. Med.202329102625263210.1038/s41591‑023‑02532‑z37640861
     [Google Scholar]
  13. MullensW. DauwJ. MartensP. VerbruggeF.H. NijstP. MeekersE. TartagliaK. ChenotF. MoubayedS. DierckxR. BlouardP. TroisfontainesP. DerthooD. SmoldersW. BruckersL. DroogneW. Ter MaatenJ.M. DammanK. LassusJ. MebazaaA. FilippatosG. RuschitzkaF. DupontM. Acetazolamide in acute decompensated heart failure with volume overload.N. Engl. J. Med.2022387131185119510.1056/NEJMoa220309436027559
     [Google Scholar]
  14. a) YeohS.E. OsmanskaJ. PetrieM.C. BrooksbankK.J.M. ClarkA.L. DochertyK.F. FoleyP.W.X. GuhaK. HallidayC.A. JhundP.S. KalraP.R. McKinleyG. LangN.N. LeeM.M.Y. McConnachieA. McDermottJ.J. PlatzE. SartipyP. SeedA. StanleyB. WeirR.A.P. WelshP. McMurrayJ.J.V. CampbellR.T. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics.Eur. Heart J.202344312966297710.1093/eurheartj/ehad34137210742
     [Google Scholar]
  15. bCox ZL, Collins SP, Hernandez GA et al. Efficacy and safety of dapagliflozin in patients with acute heart failure.J Am Coll Cardiol202483141295130610.1016/j.jacc.2024.02.00938569758
     [Google Scholar]
  16. TrullàsJ.C. Morales-RullJ.L. CasadoJ. Carrera-IzquierdoM. Sánchez-MartelesM. Conde-MartelA. Dávila-RamosM.F. LlácerP. Salamanca-BautistaP. Pérez-SilvestreJ. PlasínM.Á. CerqueiroJ.M. GilP. FormigaF. ManzanoL. MoralesJ.L. SoléC. CarreraM. LeónM. SánchezM. HornaV.G. CondeA. MenesesM.H. DávilaM.F. CarballoC.H. CasadoJ. ZabaletaJ.P. IborraP.L. GarcíaM.C.M. TrullàsJ.C. BisbeJ. del Prado Salamanca BautistaM. BodasÓ.A. ManzanoL. RuizR. SilvestreJ.P. PlasínM.Á. GonzálezJ.M.C. ChiviteD. FormigaF. GilP. JordanaR. VillalongaM. RubioM.I.P. RodrigoJ.M.C. Pérez-BarqueroM.M. MuelaA. MateosL. GrauJ. ArmengouA. HerreroA. LópezR.Q. Combining loop with thiazide diuretics for decompensated heart failure: The CLOROTIC trial.Eur. Heart J.202344541142110.1093/eurheartj/ehac68936423214
     [Google Scholar]
  17. PiardiDS ButzkeM MazzucaACM Effect of adding hydrochlorothiazide to usual treatment of patients with acute decompensated heart failure: A randomized clinical trial.Sci Rep20211111647410.1038/s41598‑021‑96002‑6
     [Google Scholar]
  18. CoxZ.L. CollinsS.P. AaronM. HernandezG.A. IiiA.T.M. DavidsonB.T. FowlerM. LindsellC.J. JrF.E.H. JenkinsC.A. KampeC. MillerK.F. StubblefieldW.B. LindenfeldJ. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.Am. Heart J.202123211612410.1016/j.ahj.2020.10.07133144086
     [Google Scholar]
  19. Fonseca-CorreaJ.I. Correa-RotterR. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: A review.Front. Med.2021877786110.3389/fmed.2021.77786134988095
     [Google Scholar]
  20. HäringH.U. MerkerL. Seewaldt-BeckerE. WeimerM. MeinickeT. BroedlU.C. WoerleH.J. Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial.Diabetes Care20143761650165910.2337/dc13‑210524722494
     [Google Scholar]
  21. KovacsC.S. SeshiahV. SwallowR. JonesR. RattundeH. WoerleH.J. BroedlU.C. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial.Diabetes Obes. Metab.201416214715810.1111/dom.1218823906415
     [Google Scholar]
  22. KomoroskiB. VachharajaniN. FengY. LiL. KornhauserD. PfisterM. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.Clin. Pharmacol. Ther.200985551351910.1038/clpt.2008.25019129749
     [Google Scholar]
  23. WiviottS.D. RazI. BonacaM.P. MosenzonO. KatoE.T. CahnA. SilvermanM.G. ZelnikerT.A. KuderJ.F. MurphyS.A. BhattD.L. LeiterL.A. McGuireD.K. WildingJ.P.H. RuffC.T. Gause-NilssonI.A.M. FredrikssonM. JohanssonP.A. LangkildeA.M. SabatineM.S. Dapagliflozin and cardiovascular outcomes in type 2 diabetes.N. Engl. J. Med.2019380434735710.1056/NEJMoa181238930415602
     [Google Scholar]
  24. McMurrayJ.J.V. SolomonS.D. InzucchiS.E. KøberL. KosiborodM.N. MartinezF.A. PonikowskiP. SabatineM.S. AnandI.S. BělohlávekJ. BöhmM. ChiangC.E. ChopraV.K. de BoerR.A. DesaiA.S. DiezM. DrozdzJ. DukátA. GeJ. HowlettJ.G. KatovaT. KitakazeM. LjungmanC.E.A. MerkelyB. NicolauJ.C. O’MearaE. PetrieM.C. VinhP.N. SchouM. TereshchenkoS. VermaS. HeldC. DeMetsD.L. DochertyK.F. JhundP.S. BengtssonO. SjöstrandM. LangkildeA.M. Dapagliflozin in patients with heart failure and reduced ejection fraction.N. Engl. J. Med.2019381211995200810.1056/NEJMoa191130331535829
     [Google Scholar]
  25. VaduganathanM. DochertyK.F. ClaggettB.L. JhundP.S. de BoerR.A. HernandezA.F. InzucchiS.E. KosiborodM.N. LamC.S.P. MartinezF. ShahS.J. DesaiA.S. McMurrayJ.J.V. SolomonS.D. SGLT2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials.Lancet20224001035475776710.1016/S0140‑6736(22)01429‑536041474
     [Google Scholar]
  26. GittoM. VillaschiA. FedericiM. CondorelliG. StefaniniG.G. The emerging role of sodium-glucose cotransporter 2 inhibitors in heart failure.Curr. Pharm. Des.202329748149310.2174/138161282966623021714332436799420
     [Google Scholar]
  27. PackerM. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis.Circulation2022146181383140510.1161/CIRCULATIONAHA.122.06173236315602
     [Google Scholar]
  28. FeigP.U. Cellular mechanism of action of loop diuretics: Implications for drug effectiveness and adverse effects.Am. J. Cardiol.1986572A14A1910.1016/0002‑9149(86)91001‑53511652
     [Google Scholar]
  29. ArumughamVB ShahinMH Therapeutic Uses of Diuretic AgentsStatPearls Publishing2023
     [Google Scholar]
  30. FelkerG.M. EllisonD.H. MullensW. CoxZ.L. TestaniJ.M. Diuretic therapy for patients with heart failure.J. Am. Coll. Cardiol.202075101178119510.1016/j.jacc.2019.12.05932164892
     [Google Scholar]
  31. Costello-BoerrigterL.C. BoerrigterG. BurnettJ.C.Jr V2 receptor antagonism with tolvaptan in heart failure.Expert Opin. Investig. Drugs200716101639164710.1517/13543784.16.10.163917922627
     [Google Scholar]
  32. Costello-BoerrigterL.C. BoerrigterG. BurnettJ.C.Jr Pharmacology of vasopressin antagonists.Heart Fail. Rev.2009142758210.1007/s10741‑008‑9108‑818766438
     [Google Scholar]
  33. CoxZ.L. TestaniJ.M. Loop diuretic resistance complicating acute heart failure.Heart Fail. Rev.202025113314510.1007/s10741‑019‑09851‑931520280
     [Google Scholar]
  34. SinghD. ShresthaK. TestaniJ.M. VerbruggeF.H. DupontM. MullensW. TangW.H.W. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure.J. Card. Fail.201420639239910.1016/j.cardfail.2014.03.00624704538
     [Google Scholar]
  35. TestaniJ.M. HanbergJ.S. ChengS. RaoV. OnyebekeC. LaurO. KulaA. ChenM. WilsonF.P. DarlingtonA. BellumkondaL. JacobyD. TangW.H.W. ParikhC.R. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure.Circ. Heart Fail.201691e00237010.1161/CIRCHEARTFAILURE.115.00237026721915
     [Google Scholar]
  36. CoxZ.L. HungR. LenihanD.J. TestaniJ.M. Diuretic strategies for loop diuretic resistance in acute heart failure.JACC Heart Fail.20208315716810.1016/j.jchf.2019.09.01231838029
     [Google Scholar]
  37. TestaniJ.M. BriscoM.A. TurnerJ.M. SpatzE.S. BellumkondaL. ParikhC.R. TangW.H.W. Loop diuretic efficiency: A metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure.Circ. Heart Fail.20147226127010.1161/CIRCHEARTFAILURE.113.00089524379278
     [Google Scholar]
  38. BrinkleyD.M.Jr BurpeeL.J. ChaudhryS.P. SmallwoodJ.A. LindenfeldJ. LakdawalaN.K. DesaiA.S. StevensonL.W. Spot urine sodium as triage for effective diuretic infusion in an ambulatory heart failure unit.J. Card. Fail.201824634935410.1016/j.cardfail.2018.01.00929410227
     [Google Scholar]
  39. VoorsA.A. DavisonB.A. TeerlinkJ.R. FelkerG.M. CotterG. FilippatosG. GreenbergB.H. PangP.S. LevinB. HuaT.A. SeverinT. PonikowskiP. MetraM. Diuretic response in patients with acute decompensated heart failure: Characteristics and clinical outcome-an analysis from RELAX-AHF.Eur. J. Heart Fail.201416111230124010.1002/ejhf.17025287144
     [Google Scholar]
  40. ValenteM.A.E. VoorsA.A. DammanK. Van VeldhuisenD.J. MassieB.M. O’ConnorC.M. MetraM. PonikowskiP. TeerlinkJ.R. CotterG. DavisonB. ClelandJ.G.F. GivertzM.M. BloomfieldD.M. FiuzatM. DittrichH.C. HillegeH.L. Diuretic response in acute heart failure: Clinical characteristics and prognostic significance.Eur. Heart J.201435191284129310.1093/eurheartj/ehu06524585267
     [Google Scholar]
  41. ter MaatenJ.M. DunningA.M. ValenteM.A.E. DammanK. EzekowitzJ.A. CaliffR.M. StarlingR.C. van der MeerP. O’ConnorC.M. SchulteP.J. TestaniJ.M. HernandezA.F. TangW.H.W. VoorsA.A. Diuretic response in acute heart failure: An analysis from ASCEND-HF.Am. Heart J.20151702313321.e410.1016/j.ahj.2015.05.00326299229
     [Google Scholar]
  42. ChenH.H. AnstromK.J. GivertzM.M. StevensonL.W. SemigranM.J. GoldsmithS.R. BartB.A. BullD.A. StehlikJ. LeWinterM.M. KonstamM.A. HugginsG.S. RouleauJ.L. O’MearaE. TangW.H.W. StarlingR.C. ButlerJ. DeswalA. FelkerG.M. O’ConnorC.M. BonitaR.E. MarguliesK.B. CappolaT.P. OfiliE.O. MannD.L. Dávila-RománV.G. McNultyS.E. BorlaugB.A. VelazquezE.J. LeeK.L. ShahM.R. HernandezA.F. BraunwaldE. RedfieldM.M. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE acute heart failure randomized trial.JAMA2013310232533254310.1001/jama.2013.28219024247300
     [Google Scholar]
  43. GottliebS.S. StebbinsA. VoorsA.A. HasselbladV. EzekowitzJ.A. CaliffR.M. O’ConnorC.M. StarlingR.C. HernandezA.F. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: Results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure).J. Am. Coll. Cardiol.201362131177118310.1016/j.jacc.2013.04.07323747790
     [Google Scholar]
  44. IkedaY. IshiiS. MaemuraK. OkiT. YazakiM. FujitaT. NabetaT. MaekawaE. KoitabashiT. AkoJ. Association between intestinal oedema and oral loop diuretic resistance in hospitalized patients with acute heart failure.ESC Heart Fail.2021854067407610.1002/ehf2.1352534323025
     [Google Scholar]
  45. BraterD.C. Pharmacokinetics of loop diuretics in congestive heart failure.Heart1994722 SupplSuppl.S40S4310.1136/hrt.72.2_Suppl.S407946757
     [Google Scholar]
  46. BraterD.C. ChennavasinP. SeiwellR. Furosemide in patients with heart failure: Shift in dose-response curves.Clin. Pharmacol. Ther.198028218218610.1038/clpt.1980.1487398185
     [Google Scholar]
  47. KoeppenB.M. StantonB.A. Physiology of diuretic action.Ren. Physiol.2013103-416717810.1016/B978‑0‑323‑08691‑2.00010‑73452853
     [Google Scholar]
  48. KnaufH. MutschlerE. Sequential nephron blockade breaks resistance to diuretics in edematous states.J. Cardiovasc. Pharmacol.199729336737210.1097/00005344‑199703000‑000109125675
     [Google Scholar]
  49. ImielaT. BudajA. Acetazolamide as add-on diuretic therapy in exacerbations of chronic heart failure: A pilot study.Clin. Drug Investig.201737121175118110.1007/s40261‑017‑0577‑128965280
     [Google Scholar]
  50. VerbruggeF.H. MartensP. AmelootK. HaemelsV. PendersJ. DupontM. TangW.H.W. DroognéW. MullensW. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.Eur. J. Heart Fail.201921111415142210.1002/ejhf.147831074184
     [Google Scholar]
  51. MartensP. VerbruggeF.H. DauwJ. NijstP. MeekersE. AugustoS.N.Jr Ter MaatenJ.M. HeylenL. DammanK. MebazaaA. FilippatosG. RuschitzkaF. TangW.H.W. DupontM. MullensW. Pre-treatment bicarbonate levels and decongestion by acetazolamide: The ADVOR trial.Eur. Heart J.202344221995200510.1093/eurheartj/ehad23637138385
     [Google Scholar]
  52. HallowK.M. HelmlingerG. GreasleyP.J. McMurrayJ.J.V. BoultonD.W. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.Diabetes Obes. Metab.201820347948710.1111/dom.1312629024278
     [Google Scholar]
  53. DunlayS.M. GivertzM.M. AguilarD. AllenL.A. ChanM. DesaiA.S. DeswalA. DicksonV.V. KosiborodM.N. LekavichC.L. McCoyR.G. MentzR.J. PiñaI.L. Type 2 diabetes mellitus and heart failure: A scientific statement from the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update.Circulation20191407e294e32410.1161/CIR.000000000000069131167558
     [Google Scholar]
  54. ShindlerD.M. KostisJ.B. YusufS. QuinonesM.A. PittB. StewartD. PinkettT. GhaliJ.K. WilsonA.C. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry.Am. J. Cardiol.199677111017102010.1016/S0002‑9149(97)89163‑18644628
     [Google Scholar]
  55. FromA.M. LeibsonC.L. BursiF. RedfieldM.M. WestonS.A. JacobsenS.J. RodehefferR.J. RogerV.L. Diabetes in heart failure: Prevalence and impact on outcome in the population.Am. J. Med.2006119759159910.1016/j.amjmed.2006.05.02416828631
     [Google Scholar]
  56. SalvatoreT. PafundiP.C. GalieroR. AlbaneseG. Di MartinoA. CaturanoA. VetranoE. RinaldiL. SassoF.C. The diabetic cardiomyopathy: The contributing pathophysiological mechanisms.Front. Med.2021869579210.3389/fmed.2021.69579234277669
     [Google Scholar]
  57. MacDonaldM.R. PetrieM.C. VaryaniF. OstergrenJ. MichelsonE.L. YoungJ.B. SolomonS.D. GrangerC.B. SwedbergK. YusufS. PfefferM.A. McMurrayJ.J.V. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme.Eur. Heart J.200829111377138510.1093/eurheartj/ehn15318413309
     [Google Scholar]
  58. de Miguel-YanesJ.M. Gonzalo-HernandoC. Muñoz-RivasN. Méndez-BailónM. Cava-ValencianoF. Torres-MachoJ. First plasma glucose value after urgent admission and in-hospital mortality in acutely decompensated heart failure.Heart Lung201544213714010.1016/j.hrtlng.2014.11.00625534479
     [Google Scholar]
  59. KosiborodM. InzucchiS.E. SpertusJ.A. WangY. MasoudiF.A. HavranekE.P. KrumholzH.M. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure.Circulation2009119141899190710.1161/CIRCULATIONAHA.108.82184319332465
     [Google Scholar]
  60. KosiborodM.N. AbildstrømS.Z. BorlaugB.A. ButlerJ. RasmussenS. DaviesM. HovinghG.K. KitzmanD.W. LindegaardM.L. MøllerD.V. ShahS.J. TreppendahlM.B. VermaS. AbhayaratnaW. AhmedF.Z. ChopraV. EzekowitzJ. FuM. ItoH. LelonekM. MelenovskyV. MerkelyB. NúñezJ. PernaE. SchouM. SenniM. SharmaK. Van der MeerP. von LewinskiD. WolfD. PetrieM.C. Semaglutide in patients with heart failure with preserved ejection fraction and obesity.N. Engl. J. Med.2023389121069108410.1056/NEJMoa230696337622681
     [Google Scholar]
  61. VillaschiA. FerranteG. CannataF. PiniD. PagnesiM. CorradaE. ReimersB. MehranR. FedericiM. SavareseG. MetraM. CondorelliG. StefaniniG.G. ChiaritoM. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: An updated systematic review and meta-analysis.Clin. Res. Cardiol.2024113689890910.1007/s00392‑023‑02362‑638252145
     [Google Scholar]
  62. SchulzeP.C. BogovikuJ. WestphalJ. AftanskiP. HaertelF. GrundS. von HaehlingS. SchumacherU. Möbius-WinklerS. BuschM. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF).Circulation2022146428929810.1161/CIRCULATIONAHA.122.05903835766022
     [Google Scholar]
  63. DammanK. BeusekampJ.C. BoorsmaE.M. SwartH.P. SmildeT.D.J. ElvanA. van EckJ.W.M. HeerspinkH.J.L. VoorsA.A. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).Eur. J. Heart Fail.202022471372210.1002/ejhf.171331912605
     [Google Scholar]
  64. RaoV.S. PlanavskyN. HanbergJ.S. AhmadT. Brisco-BacikM.A. WilsonF.P. JacobyD. ChenM. TangW.H.W. CherneyD.Z.I. EllisonD.H. TestaniJ.M. Compensatory distal reabsorption drives diuretic resistance in human heart failure.J. Am. Soc. Nephrol.201728113414342410.1681/ASN.201611117828739647
     [Google Scholar]
  65. SigurdB. OlesenK.H. WennevoldA. The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure.Am. Heart J.197589216317010.1016/0002‑8703(75)90041‑11090132
     [Google Scholar]
  66. PonikowskiP. VoorsA.A. AnkerS.D. BuenoH. ClelandJ.G.F. CoatsA.J.S. FalkV. González-JuanateyJ.R. HarjolaV-P. JankowskaE.A. JessupM. LindeC. NihoyannopoulosP. ParissisJ.T. PieskeB. RileyJ.P. RosanoG.M.C. RuilopeL.M. RuschitzkaF. RuttenF.H. van der MeerP. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur. Heart J.201637272129220010.1093/eurheartj/ehw12827206819
     [Google Scholar]
  67. JentzerJ.C. DeWaldT.A. HernandezA.F. Combination of loop diuretics with thiazide-type diuretics in heart failure.J. Am. Coll. Cardiol.201056191527153410.1016/j.jacc.2010.06.03421029871
     [Google Scholar]
  68. Brisco-BacikM.A. ter MaatenJ.M. HouserS.R. VedageN.A. RaoV. AhmadT. WilsonF.P. TestaniJ.M. Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: A propensity analysis.J. Am. Heart Assoc.2018718e00914910.1161/JAHA.118.00914930371181
     [Google Scholar]
  69. FilippatosG. AnkerS.D. BöhmM. GheorghiadeM. KøberL. KrumH. MaggioniA.P. PonikowskiP. VoorsA.A. ZannadF. KimS.Y. NowackC. PalomboG. KolkhofP. Kimmeskamp-KirschbaumN. PieperA. PittB. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.Eur. Heart J.201637272105211410.1093/eurheartj/ehw13227130705
     [Google Scholar]
  70. PandeyA.K. BhattD.L. CosentinoF. MarxN. RotsteinO. PittB. PandeyA. ButlerJ. VermaS. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.Eur. Heart J.202243312931294510.1093/eurheartj/ehac29935713973
     [Google Scholar]
  71. PittB. Effectiveness of spironolactone added to an angiotensin- converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).Am. J. Cardiol.199678890290710.1016/S0002‑9149(96)00465‑18888663
     [Google Scholar]
  72. GirerdN. PangP.S. SwedbergK. FoughtA. KwasnyM.J. SubaciusH. KonstamM.A. MaggioniA. GheorghiadeM. ZannadF. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: Analysis from the EVEREST trial.Eur. J. Heart Fail.201315111228123510.1093/eurjhf/hft10023787720
     [Google Scholar]
  73. AbdallahJ.G. SchrierR.W. EdelsteinC. JenningsS.D. WyseB. EllisonD.H. Loop diuretic infusion increases thiazide-sensitive Na+/ Cl-cotransporter abundance.J. Am. Soc. Nephrol.20011271335134110.1681/ASN.V127133511423562
     [Google Scholar]
  74. HensenJ. AbrahamW.T. DürrJ.A. SchrierR.W. Aldosterone in congestive heart failure: Analysis of determinants and role in sodium retention.Am. J. Nephrol.199111644144610.1159/0001683561840232
     [Google Scholar]
  75. van VlietA. DonkerA.J.M. NautaJ.J.P. VerheugtF.W.A. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.Am. J. Cardiol.1993713A21A2810.1016/0002‑9149(93)90241‑48422000
     [Google Scholar]
  76. FerreiraJ.P. SantosM. AlmeidaS. MarquesI. BettencourtP. CarvalhoH. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.Eur. J. Intern. Med.2014251677210.1016/j.ejim.2013.08.71124070521
     [Google Scholar]
  77. ButlerJ. AnstromK.J. FelkerG.M. GivertzM.M. KalogeropoulosA.P. KonstamM.A. MannD.L. MarguliesK.B. McNultyS.E. MentzR.J. RedfieldM.M. TangW.H.W. WhellanD.J. ShahM. Desvigne-NickensP. HernandezA.F. BraunwaldE. Efficacy and safety of spironolactone in acute heart failure.JAMA Cardiol.20172995095810.1001/jamacardio.2017.219828700781
     [Google Scholar]
  78. AsakuraM. ItoS. YamadaT. SaitoY. KimuraK. YamashinaA. HirayamaA. KobayashiY. HanataniA. TsujimotoM. YasudaS. AbeY. HigashinoY. TamakiY. SuginoH. NiinumaH. OkuharaY. KoitabashiT. MomomuraS.I. AsaiK. NomuraA. KawaiH. SatohY. YoshikawaT. HirataK.I. YokoiY. TanakaJ. ShibataY. MaejimaY. TamakiS. KawataH. IwahashiN. KobayashiM. HiguchiY. KadaA. YamamotoH. KitakazeM. Efficacy and safety of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER trial): A multicentre, randomized, double-blind, placebo-controlled trial.Eur. Heart J. Cardiovasc. Pharmacother.20228210811710.1093/ehjcvp/pvaa13233175088
     [Google Scholar]
  79. GheorghiadeM. KonstamM.A. BurnettJ.C.Jr GrinfeldL. MaggioniA.P. SwedbergK. UdelsonJ.E. ZannadF. CookT. OuyangJ. ZimmerC. OrlandiC. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials.JAMA2007297121332134310.1001/jama.297.12.133217384438
     [Google Scholar]
  80. KonstamM.A. GheorghiadeM. BurnettJ.C.Jr GrinfeldL. MaggioniA.P. SwedbergK. UdelsonJ.E. ZannadF. CookT. OuyangJ. ZimmerC. OrlandiC. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial.JAMA2007297121319133110.1001/jama.297.12.131917384437
     [Google Scholar]
  81. HauptmanP.J. BurnettJ. GheorghiadeM. GrinfeldL. KonstamM.A. KosticD. KrasaH.B. MaggioniA. OuyangJ. SwedbergK. ZannadF. ZimmerC. UdelsonJ.E. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.J. Card. Fail.201319639039710.1016/j.cardfail.2013.04.00123743487
     [Google Scholar]
  82. KonstamM.A. KiernanM. ChandlerA. DhingraR. ModyF.V. EisenH. HaughtW.H. WagonerL. GuptaD. PattenR. GordonP. KorrK. FilecciaR. PresslerS.J. GregoryD. WedgeP. DowlingD. RomelingM. KonstamJ.M. MassaroJ.M. UdelsonJ.E. Short-term effects of tolvaptan in patients with acute heart failure and volume overload.J. Am. Coll. Cardiol.201769111409141910.1016/j.jacc.2016.12.03528302292
     [Google Scholar]
  83. FelkerG.M. MentzR.J. ColeR.T. AdamsK.F. EgnaczykG.F. FiuzatM. PatelC.B. EcholsM. KhouriM.G. TaurasJ.M. GuptaD. MondsP. RobertsR. O’ConnorC.M. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure.J. Am. Coll. Cardiol.201769111399140610.1016/j.jacc.2016.09.00427654854
     [Google Scholar]
  84. HodsonD.Z. GriffinM. MahoneyD. RaghavendraP. AhmadT. TurnerJ. WilsonF.P. TangW.H.W. RaoV.S. CollinsS.P. MullensW. TestaniJ.M. Natriuretic response is highly variable and associated with 6-month survival.JACC Heart Fail.20197538339110.1016/j.jchf.2019.01.00731047017
     [Google Scholar]
  85. CostanzoM.R. GuglinM.E. SaltzbergM.T. JessupM.L. BartB.A. TeerlinkJ.R. JaskiB.E. FangJ.C. FellerE.D. HaasG.J. AndersonA.S. SchollmeyerM.P. SobotkaP.A. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.J. Am. Coll. Cardiol.200749667568310.1016/j.jacc.2006.07.07317291932
     [Google Scholar]
  86. SrivastavaM. HarrisonN. CaetanoA.F.S.M.A. TanA.R. LawM. Ultrafiltration for acute heart failure.Cochrane Libr.202220221CD01359310.1002/14651858.CD013593.pub235061249
     [Google Scholar]
  87. ElkayamU. NgT.M.H. HatamizadehP. JanmohamedM. MehraA. Renal vasodilatory action of dopamine in patients with heart failure.Circulation2008117220020510.1161/CIRCULATIONAHA.107.73710618172028
     [Google Scholar]
  88. WanS.H. StevensS.R. BorlaugB.A. AnstromK.J. DeswalA. FelkerG.M. GivertzM.M. BartB.A. TangW.H.W. RedfieldM.M. ChenH.H. Differential response to low-dose dopamine or low-dose nesiritide in acute heart failure with reduced or preserved ejection fraction.Circ. Heart Fail.201698e00259310.1161/CIRCHEARTFAILURE.115.00259327512103
     [Google Scholar]
  89. LiuC. LiuK. Effects of glucocorticoids in potentiating diuresis in heart failure patients with diuretic resistance.J. Card. Fail.201420962562910.1016/j.cardfail.2014.06.35324969700
     [Google Scholar]
  90. LiuC. LiuG. ZhouC. JiZ. ZhenY. LiuK. Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance.Can. J. Cardiol.2007231186586810.1016/S0828‑282X(07)70840‑117876376
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128316596240625110337
Loading
Diuretic Combination Therapy in Acute Heart Failure: An Updated Review
Curr. Pharm. Des. 30, 2597 (2024); https://doi.org/10.2174/0113816128316596240625110337
/content/journals/cpd/10.2174/0113816128316596240625110337
/content/journals/cpd/10.2174/0113816128316596240625110337
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Acute heart failure; decongestion; diuretic combination; diuretic resistance; inhibitors; loop diuretic

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test